BRIDGE-SIC Efficacy Trial

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT07735442
Status
Recruiting
Apply to this trial

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LLM-generated SIC summary email to clinical teams — BEHAVIORAL
    An email containing a summary of prior serious illness conversations, generated by a large language model, is sent to the patient's clinical teams at admission, prompting review and discussion of care preferences.

Study Details

This is a pragmatic, prospective, randomized clinical trial to test the effectiveness of large language model (LLM)-generated serious illness conversation (SIC) summaries delivered to patients' inpatient and outpatient clinicians at the time of hospital admission on the primary outcome of days in the hospital in the next 90 days.

Key Dates

First listed
Jul 30, 2026
Start date
Aug 4, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
600 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Arm 1: Intervention Arm
    An email is sent to patients' inpatient and outpatient clinical teams containing an LLM-generated summary of prior SIC documentation, prompting clinicians to review and discuss care preferences with the patient and align care with patient goals.
  • No Intervention: Arm 2: Control Arm
    Patients receive standard of care; SICs may be initiated by patients or clinicians as usual.

Primary Outcome Measure

Number of Days in the Hospital [ Time Frame: 90 days after randomization ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02214
Alexi A Wright, MD.MPH
[email protected]
617-632-2334
Charlotta J Lindvall, MD PhD
[email protected]
6175823401
Alexi A Wright, MD, MPH (PRINCIPAL_INVESTIGATOR)
Charlotta J Lindvall, MD PhD (PRINCIPAL_INVESTIGATOR)
Dana Farber Cancer InstituteBostonMassachusetts02215
Alexi A Wright, MD. MPH
[email protected]
617-632-2334
Alexi A Wright, MD, MPH
[email protected]
6176322334
Alexi A Wright, MD, MPH (PRINCIPAL_INVESTIGATOR)
Charlotta J Lindvall, MD PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MADana Farber Cancer Institute· Boston, MA

Related Studies